Undertreatment of osteoporosis following hip fracture: a retrospective, observational study in Singapore

被引:19
作者
Chau, Yi Ting [1 ]
Nashi, Nazrul [2 ]
Law, Lawrence Siu-Chun [1 ]
Goh, Raymond Kai Heng [3 ]
Choo, Selena Xueli [2 ]
Seetharaman, Santhosh Kumar [1 ]
机构
[1] Alexandra Hosp, 378 Alexandra Rd, Singapore, Singapore
[2] Natl Univ Singapore Hosp, Univ Orthopaed Hand & Reconstruct Microsurg Clust, 5 Lower Kent Ridge Rd, Singapore, Singapore
[3] Sengkang Gen Hosp, 110 Sengkang East Way, Singapore, Singapore
关键词
Osteoporosis; Hip fracture; Compliance; Persistence to treatment; HEALTH BELIEFS; FRAGILITY FRACTURE; INCIDENT FRACTURES; OLDER WOMEN; PREVENTION; MORTALITY; RISK; CARE; HOSPITALIZATION; METAANALYSIS;
D O I
10.1007/s11657-020-00816-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Undertreatment of osteoporosis after hip fracture increases the risk of death, disability, recurrent osteoporotic fractures, and financial burden. Only half were compliant with osteoporosis medications. Elderly patients were less persistent and compliant to treatment. Denosumab was associated with a higher proportion of days covered by osteoporosis medications than oral bisphosphonates. Purpose The aim of this study was to identify factors that contributed to the initiation of osteoporosis medications following hip fracture as well as the compliance and persistence to osteoporosis medications. Methods Clinical data of 532 patients older than 50 years old admitted for surgical fixation of hip fractures were reviewed. Three hundred forty-seven had sufficient data for analysis after excluding patients with non-fragility fractures. Prescription for any osteoporosis medication in the year following hip fracture as well as compliance to treatment was evaluated. Results Only 40.3% of patients were prescribed with osteoporosis medication within 1 year post-hip fracture. Females (p =0.020) performing dual-energy x-ray absorptiometry scan (p <0.001) and 25 hydroxyvitamin D levels testing post-hip fracture (p <0.027) were independent determinants of increased likelihood of being prescribed with osteoporosis medication. Patients with proportion of days covered (PDC) >= 0.8 (or 80% of days covered in a year) were defined as compliant. Overall, only 49.7% of the patients were compliant with osteoporosis medications. Elderly patients aged 70-79 years (p =0.002) and males (p =0.017) were less persistent with osteoporosis treatment when compared with patients aged < 69 years and females. The compliance was poorer in patients aged 70-79 years (p= 0.026) as compared with those under 69 years of age. Statistically significant difference (p =0.032) was observed between mean PDC of oral bisphosphonates (0.66) and denosumab (0.83). Only 39.3% of patients were persistent with treatment at 1 year. Conclusion Our findings demonstrate the urgent need to increase awareness through a structured protocol of osteoporosis treatment. A multi-disciplinary Fracture Liaison Service should be set up to ensure compliance to osteoporosis medication post-hip fracture.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] After the fall: improving osteoporosis treatment following hip fracture
    Kuiper, B. W.
    Graybill, S.
    Tate, J. M.
    Kaufman, N.
    Bersabe, D.
    OSTEOPOROSIS INTERNATIONAL, 2018, 29 (06) : 1295 - 1301
  • [32] Improving care after hip fracture: the fracture? Think osteoporosis (FTOP) program
    Dore, Naomi
    Kennedy, Courtney
    Fisher, Pauline
    Dolovich, Lisa
    Farrauto, Leonardo
    Papaioannou, Alexandra
    BMC GERIATRICS, 2013, 13
  • [33] Osteoporosis treatment rate following hip fracture in a community hospital
    Aliya A. Khan
    Hajar AbuAlrob
    Farhan Tariq
    Madiha Tauqir
    Paul Zalzal
    Iman M’Hiri
    Moin Khan
    Mark Ginty
    Brad Weening
    Archives of Osteoporosis, 2021, 16
  • [34] Hip fracture rate and osteoporosis treatment in Ontario: A population-based retrospective cohort study
    Abualrob, Hajar
    Ioannidis, George
    Jaglal, Susan
    Costa, Andrew
    Grifith, Lauren E.
    Thabane, Lehana
    Adachi, Jonathan D.
    Cameron, Cathy
    Hillier, Loretta
    Lau, Arthur
    Papaioannou, Alexandra
    ARCHIVES OF OSTEOPOROSIS, 2024, 19 (01)
  • [35] Longitudinal change in hip fracture incidence after starting risedronate or raloxifene: an observational study
    Ferrari, Serge
    Nakamura, Toshitaka
    Hagino, Hiroshi
    Fujiwara, Saeko
    Lange, Jeffrey L.
    Watts, Nelson B.
    JOURNAL OF BONE AND MINERAL METABOLISM, 2011, 29 (05) : 561 - 570
  • [36] Anti-Osteoporosis Medication Prescriptions and Incidence of Subsequent Fracture Among Primary Hip Fracture Patients in England and Wales: An Interrupted Time-Series Analysis
    Hawley, Samuel
    Leal, Jose
    Delmestri, Antonella
    Prieto-Alhambra, Daniel
    Arden, Nigel K.
    Cooper, Cyrus
    Javaid, M. Kassim
    Judge, Andrew
    JOURNAL OF BONE AND MINERAL RESEARCH, 2016, 31 (11) : 2008 - 2015
  • [37] Economic evaluation of osteoporosis liaison service for secondary fracture prevention in postmenopausal osteoporosis patients with previous hip fracture in Japan
    Moriwaki, K.
    Noto, S.
    OSTEOPOROSIS INTERNATIONAL, 2017, 28 (02) : 621 - 632
  • [38] Missed Opportunities for Osteoporosis Treatment in Patients Hospitalized for Hip Fracture
    Jennings, Lee A.
    Auerbach, Andrew D.
    Maselli, Judith
    Pekow, Penelope S.
    Lindenauer, Peter K.
    Lee, Sei J.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2010, 58 (04) : 650 - 657
  • [39] Mortality in British hip fracture patients, 2000-2010: A population-based retrospective cohort study
    Klop, Corinne
    Welsing, Paco M. J.
    Cooper, Cyrus
    Harvey, Nicholas C.
    Elders, Petra J. M.
    Bijlsma, Johannes W. J.
    Leufkens, Hubert G. M.
    de Vries, Frank
    BONE, 2014, 66 : 171 - 177
  • [40] Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study
    Brozek, W.
    Reichardt, B.
    Zwerina, J.
    Dimai, H. P.
    Klaushofer, K.
    Zwettler, E.
    OSTEOPOROSIS INTERNATIONAL, 2016, 27 (01) : 387 - 396